Bleeding Risk Following Stereotactic Body Radiation Therapy for Localized Prostate Cancer in Men on Baseline Anticoagulant or Antiplatelet Therapy
PurposePatients on anticoagulant/antiplatelet medications are at a high risk of bleeding following external beam radiation therapy for localized prostate cancer. SBRT may reduce the bleeding risk by decreasing the volume of bladder/rectum receiving high doses. This retrospective study sought to eval...
Main Authors: | Abigail Pepin, Sarthak Shah, Monica Pernia, Siyuan Lei, Marilyn Ayoob, Malika Danner, Thomas Yung, Brian T. Collins, Simeng Suy, Nima Aghdam, Sean P. Collins |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-09-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.722852/full |
Similar Items
-
Treatment Interruptions During Stereotactic Body Radiotherapy for Prostate Cancer
by: Abigail N. Pepin, et al.
Published: (2022-01-01) -
Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer in Men With a High Baseline International Prostate Symptom Score (IPSS ≥ 15)
by: Nima Aghdam, et al.
Published: (2020-07-01) -
Patient-Reported Financial Burden Following Stereotactic Body Radiation Therapy for Localized Prostate Cancer
by: Tamir N. Sholklapper, et al.
Published: (2022-03-01) -
Prostate-Specific Antigen 5 Years following Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: An Ablative Procedure?
by: Shaan Kataria, et al.
Published: (2017-07-01) -
Stereotactic Body Radiation Therapy: A Versatile, Well-Tolerated, and Effective Treatment Option for Extracranial Metastases From Primary Ovarian and Uterine Cancer
by: Nima Aghdam, et al.
Published: (2020-12-01)